IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $53.67 Average Price Target from Analysts

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $53.67.

Several research analysts have recently commented on the company. Oppenheimer restated an “outperform” rating and set a $53.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday, October 29th. Leerink Partners downgraded shares of IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $41.00 to $27.00 in a research note on Tuesday, November 5th. Stifel Nicolaus increased their price objective on IDEAYA Biosciences from $63.00 to $68.00 and gave the company a “buy” rating in a research note on Tuesday, September 10th. Leerink Partnrs cut IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $52.00 price target on shares of IDEAYA Biosciences in a research report on Tuesday.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its position in IDEAYA Biosciences by 9.8% during the third quarter. Geode Capital Management LLC now owns 1,945,455 shares of the company’s stock worth $61,645,000 after buying an additional 172,838 shares during the period. Barclays PLC grew its position in shares of IDEAYA Biosciences by 188.8% during the third quarter. Barclays PLC now owns 181,170 shares of the company’s stock worth $5,739,000 after acquiring an additional 118,438 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of IDEAYA Biosciences during the third quarter worth approximately $245,000. Two Sigma Advisers LP increased its holdings in shares of IDEAYA Biosciences by 1.7% in the 3rd quarter. Two Sigma Advisers LP now owns 468,100 shares of the company’s stock valued at $14,829,000 after acquiring an additional 7,700 shares during the period. Finally, State Street Corp boosted its stake in IDEAYA Biosciences by 15.4% during the 3rd quarter. State Street Corp now owns 3,317,936 shares of the company’s stock worth $105,112,000 after purchasing an additional 443,640 shares during the period. Institutional investors and hedge funds own 98.29% of the company’s stock.

IDEAYA Biosciences Trading Down 2.8 %

NASDAQ IDYA opened at $25.59 on Monday. The stock has a fifty day simple moving average of $28.49 and a 200-day simple moving average of $34.17. The stock has a market cap of $2.21 billion, a PE ratio of -10.98 and a beta of 0.79. IDEAYA Biosciences has a twelve month low of $24.72 and a twelve month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last announced its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the business posted ($0.46) EPS. Research analysts predict that IDEAYA Biosciences will post -2.45 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.